MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Kura Oncology Inc

Suletud

SektorTervishoid

6.19 6.72

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.8

Max

6.2

Põhinäitajad

By Trading Economics

Sissetulek

-38M

-57M

Müük

-40M

14M

Kasumimarginaal

-407.067

Töötajad

192

EBITDA

-48M

-65M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+347.5% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-34M

492M

Eelmine avamishind

-0.53

Eelmine sulgemishind

6.19

Uudiste sentiment

By Acuity

50%

50%

157 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Kura Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuli 2025, 15:46 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250 Million Private Placement

9. juuli 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 20:26 UTC

Tulu

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9. juuli 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9. juuli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9. juuli 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9. juuli 2025, 17:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9. juuli 2025, 16:14 UTC

Omandamised, ülevõtmised, äriostud

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9. juuli 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9. juuli 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9. juuli 2025, 15:31 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250M Private Placement

9. juuli 2025, 15:31 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9. juuli 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9. juuli 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9. juuli 2025, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9. juuli 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9. juuli 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Kura Oncology Inc Prognoos

Hinnasiht

By TipRanks

347.5% tõus

12 kuu keskmine prognoos

Keskmine 26 USD  347.5%

Kõrge 40 USD

Madal 8 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Kura Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

11

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

5.575 / 6.6Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

157 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.